Analysis of Sp transcription factors in the postmortem brain of chronic schizophrenia: A pilot study of relationship to negative symptoms

Journal of Psychiatric Research

Volumn 47, Issue 7, 2013, Pages 926-934

  Pinacho, Raquel ^a   Villalmanzo, Núria ^a   Roca, Mercedes ^a   Iniesta, Raquel ^a   Monje, Alfonso ^a   Haro, Josep Maria ^a   Meana, J Javier ^b   Ferrer, Isidre ^c   Gill, Grace ^d   Ramos, Belén ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cerebellum; Negative symptoms; Postmortem brain; Prefrontal cortex; Schizophrenia; Sp transcription factors

Indexed keywords

DOPAMINE 2 RECEPTOR; MESSENGER RNA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; TRANSCRIPTION FACTOR SP;

ADULT; AGED; ARTICLE; BRAIN; CADAVER; CEREBELLUM; CHRONIC DISEASE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; MALE; PILOT STUDY; POLYMERASE CHAIN REACTION; PREFRONTAL CORTEX; PRIORITY JOURNAL; SCHIZOPHRENIA; SYMPTOM;

EID: 84877134014     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2013.03.004     Document Type: Article

References (50)

1. Amador X.F., Kirkpatrick B., Buchanan R.W., Carpenter W.T., Marcinko L., Yale S.A. Stability of the diagnosis of deficit syndrome in schizophrenia. American Journal of Psychiatry 1999, 156:637-639.
2. Andersen C.L., Jensen J.L., Orntoft T.F. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Research 2004, 64:5245-5250.
3. Arndt S., Andreasen N.C., Flaum M., Miller D., Nopoulos P. A longitudinal study of symptom dimensions in schizophrenia. Prediction and patterns of change. Archives of General Psychiatry 1995, 52:352-360.
4. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society: Series B 1995, 57:289-300.
5. Ben-Shachar D., Karry R. Sp1 expression is disrupted in schizophrenia; a possible mechanism for the abnormal expression of mitochondrial complex I genes, NDUFV1 and NDUFV2. PLoS One 2007, 2. e817.
6. Berrettini W.H. Are schizophrenic and bipolar disorders related? A review of family and molecular studies. Biological Psychiatry 2000, 48:531-538.
7. Borde M., Davis E.J., Sharma L.N. The stability of symptoms and syndromes in chronic schizophrenic patients. Indian Journal of Psychiatry 1992, 34:133-139.
8. Bouwman P., Philipsen S. Regulation of the activity of Sp1-related transcription factors. Molecular and Cellular Endocrinology 2002, 195:27-38.
9. Carpenter W.T., Kirkpatrick B., Buchanan R.W. Schizophrenia: syndromes and diseases. Journal of Psychiatric Research 1999, 33:473-475.
10. Delawalla Z., Csernansky J.G., Barch D.M. Prefrontal cortex function in nonpsychotic siblings of individuals with schizophrenia. Biological Psychiatry 2008, 63:490-497.
11. Dror N., Klein E., Karry R., Sheinkman A., Kirsh Z., Mazor M., et al. State-dependent alterations in mitochondrial complex I activity in platelets: a potential peripheral marker for schizophrenia. Molecular Psychiatry 2002, 7:995-1001.
12. English J.A., Pennington K., Dunn M.J., Cotter D.R. The neuroproteomics of schizophrenia. Biological Psychiatry 2011, 69(2):163-172.
13. Fatemi S.H., Folsom T.D. The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophrenia Bulletin 2009, 35:528-548.
14. Friston K.J. Schizophrenia and the disconnection hypothesis. Acta Psychiatrica Scandinavica Supplementum 1999, 395:68-79.
15. Gardner D.M., Murphy A.L., O'Donnell H., Centorrino F., Baldessarini R.J. International consensus study of antipsychotic dosing. American Journal of Psychiatry 2010, 167:686-693.
16. Han I., Kudlow J.E. Reduced O glycosylation of Sp1 is associated with increased proteasome susceptibility. Molecular and Cellular Biology 1997, 17:2550-2558.
17. Haro J.M., Kamath S.A., Ochoa S., Novick D., Rele K., Fargas A., et al. The clinical global impression-schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatrica Scandinavica Supplementum 2003, 16-23.
18. Ho B.C., Mola C., Andreasen N.C. Cerebellar dysfunction in neuroleptic naive schizophrenia patients: clinical, cognitive, and neuroanatomic correlates of cerebellar neurologic signs. Biological Psychiatry 2004, 55:1146-1153.
19. Hota S.K., Hota K.B., Prasad D., Ilavazhagan G., Singh S.B. Oxidative-stress-induced alterations in Sp factors mediate transcriptional regulation of the NR1 subunit in hippocampus during hypoxia. Free Radical Biology & Medicine 2010, 49:178-191.
20. Itokawa M., Arinami T., Toru M. Advanced research on dopamine signaling to develop drugs for the treatment of mental disorders: Ser311Cys polymorphisms of the dopamine D2-receptor gene and schizophrenia. Journal of Pharmacological Sciences 2010, 114:1-5.
21. Jentsch J.D., Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1999, 20:201-225.
22. Katz D.B., Steinmetz J.E. Psychological functions of the cerebellum. Behavioral and Cognitive Neuroscience Reviews 2002, 1:229-241.
23. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987, 13:261-276.
24. Konarski J.Z., McIntyre R.S., Grupp L.A., Kennedy S.H. Is the cerebellum relevant in the circuitry of neuropsychiatric disorders?. Journal of Psychiatry & Neuroscience 2005, 30:178-186.
25. Konradi C. Gene expression microarray studies in polygenic psychiatric disorders: applications and data analysis. Brain Research. Brain Research Reviews 2005, 50:142-155.
26. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Archives of General Psychiatry 1994, 51:199-214.
27. Lane H.Y., Lee C.C., Chang Y.C., Lu C.T., Huang C.H., Chang W.H. Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function. International Journal of Neuropsychopharmacology 2004, 7:461-470.
28. Lin C.Y., Sawa A., Jaaro-Peled H. Better understanding of mechanisms of schizophrenia and bipolar disorder: from human gene expression profiles to mouse models. Neurobiology of Disease 2011, 45:48-56.
29. Liu A., Zhuang Z., Hoffman P.W., Bai G. Functional analysis of the rat N-methyl-d-aspartate receptor 2A promoter: multiple transcription starts points, positive regulation by Sp factors, and translational regulation. Journal of Biological Chemistry 2003, 278:26423-26434.
30. Picard H., Amado I., Mouchet-Mages S., Olie J.P., Krebs M.O. The role of the cerebellum in schizophrenia: an update of clinical, cognitive, and functional evidences. Schizophrenia Bulletin 2008, 34:155-172.
31. Pinacho R., Villalmanzo N., Lalonde J., Haro J.M., Meana J.J., Gill G., et al. The transcription factor SP4 is reduced in postmortem cerebellum of bipolar disorder subjects: control by depolarization and lithium. Bipolar Disorder 2011, 13:474-485.
32. Qian K., Di Lieto A., Corander J., Auvinen P., Greco D. Re-analysis of bipolar disorder and schizophrenia gene expression complements the Kraepelinian dichotomy. Advances in Experimental Medicine and Biology 2012, 736:563-577.
33. Ramos B., Gaudilliere B., Bonni A., Gill G. Transcription factor Sp4 regulates dendritic patterning during cerebellar maturation. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:9882-9887.
34. Ramos B., Valin A., Sun X., Gill G. Sp4-dependent repression of neurotrophin-3 limits dendritic branching. Molecular and Cellular Neuroscience 2009, 42:152-159.
35. Reichenberg A., Rieckmann N., Harvey P.D. Stability in schizophrenia symptoms over time: findings from the Mount Sinai Pilgrim Psychiatric Center Longitudinal Study. Journal of Abnormal Psychology 2005, 114:363-372.
36. Rey E.R., Bailer J., Brauer W., Handel M., Laubenstein D., Stein A. Stability trends and longitudinal correlations of negative and positive syndromes within a three-year follow-up of initially hospitalized schizophrenics. Acta Psychiatrica Scandinavica 1994, 90:405-412.
37. Roca M., Escanilla A., Monje A., Baño V., Planchat L., Costa J., et al. Banco de tejidos neurológicos de Sant Joan de Déu-Serveis de Salut Mental para la investigación de las enfermendades mentales. La importancia de un programa de donación en vida. Psiquiatría Biológica 2008, 15:73-79.
38. Rothman K.J. No adjustments are needed for multiple comparisons. Epidemiology 1990, 1:43-46.
39. Suske G., Bruford E., Philipsen S. Mammalian SP/KLF transcription factors: bring in the family. Genomics 2005, 85:551-556.
40. Tandon R., Nasrallah H.A., Keshavan M.S. Schizophrenia, " just the facts" 4. Clinical features and conceptualization. Schizophrenia Research 2009, 110:1-23.
41. Thanseem I., Anitha A., Nakamura K., Suda S., Iwata K., Matsuzaki H., et al. Elevated transcription factor specificity protein 1 in autistic brains alters the expression of autism candidate genes. Biological Psychiatry 2012, 71:410-418.
42. Thomann P.A., Roebel M., Dos Santos V., Bachmann S., Essig M., Schroder J. Cerebellar substructures and neurological soft signs in first-episode schizophrenia. Psychiatry Research 2009, 173:83-87.
43. Toda M., Abi-Dargham A. Dopamine hypothesis of schizophrenia: making sense of it all. Current Psychiatry Reports 2007, 9:329-336.
44. Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biology 2002, 3. RESEARCH0034.
45. van den Oord E.J., Sullivan P.F. False discoveries and models for gene discovery. Trends in Genetics 2003, 19:537-542.
46. Wong A.H., Van Tol H.H. Schizophrenia: from phenomenology to neurobiology. Neuroscience & Biobehavioral Reviews 2003, 27:269-306.
47. Yajima S., Lee S.H., Minowa T., Mouradian M.M. Sp family transcription factors regulate expression of rat D2 dopamine receptor gene. DNA and Cell Biology 1998, 17:471-479.
48. Yeganeh-Doost P., Gruber O., Falkai P., Schmitt A. The role of the cerebellum in schizophrenia: from cognition to molecular pathways. Clinics (Sao Paulo) 2011, 66(Suppl. 1):71-77.
49. Zhou X., Long J.M., Geyer M.A., Masliah E., Kelsoe J.R., Wynshaw-Boris A., et al. Reduced expression of the Sp4 gene in mice causes deficits in sensorimotor gating and memory associated with hippocampal vacuolization. Molecular Psychiatry 2005, 10:393-406.
50. Zhou X., Tang W., Greenwood T.A., Guo S., He L., Geyer M.A., et al. Transcription factor SP4 is a susceptibility gene for bipolar disorder. PLoS One 2009, 4(4). e5196.